• Molecular NameMefenamic acid
  • SynonymAcide Mefenamique; Mefanamic Acid; Mefenacid; Mefenaminsaeure; Mephenamic Acid; Mephenaminic Acid; Methenamic Acid
  • Weight241.29
  • Drugbank_IDDB00784
  • ACS_NO61-68-7
  • Show 2D model
  • LogP (experiment)5.12
  • LogP (predicted, AB/LogP v2.0)4.94
  • pka4.2
  • LogD (pH=7, predicted)2.25
  • Solubility (experiment)0.02 mg/ml
  • LogS (predicted, ACD/Labs)(ph=7)-1.54
  • LogSw (predicted, AB/LogsW2.0)0.04
  • Sw (mg/ml) (predicted, ACD/Labs)0.03
  • No.of HBond Donors2
  • No.of HBond Acceptors3
  • No.of Rotatable Bonds3
  • TPSA49.33
  • StatusFDA approved
  • AdministrationN/A
  • PharmacologyA non-steroidal anti-inflammatory drug used to treat pain, including menstrual pain. It is typically prescribed for oral administration.
  • Absorption_value90.0
  • Absorption (description)Readily absorbed after oral administration.
  • Caco_2N/A
  • Bioavailability90.0
  • Protein binding99.0
  • Volume of distribution (VD)N/A
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmHepatic (CYP2C9). Metabolised by hydroxylation of the 3′-methyl group followed by oxidation to produce the 3′-carboxy metabolite; glucuronide conjugation also occurs.
  • Half life2~4 h
  • ExcretionAbout 52% of a dose is excreted in the urine in 48 h, 6% as mefenamic acid and the other 46% as conjugated metabolites; about 20% of a dose is eliminated in the faeces, mostly as unconjugated 3′-carboxymefenamic acid. Trace amounts of mefenamic acid may be present in breast milk.
  • Urinary ExcretionN/A
  • CleranceN/A
  • ToxicityToxic effects are usually associated with plasma concentrations greater than 10 g/L.
  • LD50 (rat)LD50=740 mg/kg
  • LD50 (mouse)LD50=2000